GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 13, 2025, titled "Press Release ".
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GlaxoSmithKline Pharmaceuticals reported full-year revenue of Rs. 3,723 crores, up 9% year-on-year. Profit After Tax (before exceptional items) rose 32% to Rs. 915 crores, and EBITDA margins expanded by 500 basis points to 31.4%. For Q4 alone, revenue was Rs. 966 crores (6% like-to-like growth) with PAT of Rs. 260 crores. The Board has recommended a final dividend of Rs. 42 per equity share for FY2024-25. The company attributed growth to its diversified portfolio across General Medicines, Specialty, and Vaccines, with key brands like Augmentin, Calpol, and Trelegy performing well. It is also preparing to launch oncology products Zejula and Jemperli in FY2025-26.
Strong full-year performance with healthy revenue growth, a 32% jump in profits, and expanding margins, supported by a final dividend of Rs. 42 per share — overall positive for shareholders and likely to be viewed favourably by the market.